Volovetsky Arthur B, Novikova Victoria A, Boloban Anastasia, Rzhevskiy Aleksej S, Kapitannikova Alina, Ovchinnikova Elena G, Klejmentjeva Tatjana P, Grishin Vladislav A, Pigareva Yana, Zvyagin Andrei V, Ebrahimi Warkiani Majid, Maslennikova Anna V
Institute for Regenerative Medicine, Sechenov University, Moscow 119991, Russia.
Central Research Laboratory, Privolzhsky Research Medical University, Nizhny Novgorod 603005, Russia.
Micromachines (Basel). 2025 Apr 15;16(4):470. doi: 10.3390/mi16040470.
Investigating the molecular and genetic characteristics of circulating tumor cells (CTCs) presents a promising approach for personalizing treatment in patients with malignant neoplasms, given the limitations of traditional biopsy and histopathology. This study aimed to isolate, characterize, and analyze CTC dynamics in the peripheral blood of 30 patients with metastatic lung cancer to develop criteria for treatment response and prognosis. We detected CTCs before the start of the treatment and monitored changes during treatment, correlating these with responses evaluated by standard imaging methods. A decrease in the CTCs in the course of the therapy was linked to a favorable tumor response, while the stable CTC counts indicated a lack of response and poor survival prognosis. The OS of patients was analyzed and compared with the initial number of CTCs in peripheral blood samples. The significant reductions in median OS were evident in patients with >3 total CTCs at baseline compared to those with ≤3 total CTCs (median survival 26 months, = 10, vs. median survival 8 months, = 19, respectively with HR = 2.6, 95% CI 1.07 to 6.4).
鉴于传统活检和组织病理学的局限性，研究循环肿瘤细胞（CTC）的分子和遗传特征为恶性肿瘤患者的个性化治疗提供了一种有前景的方法。本研究旨在分离、表征和分析30例转移性肺癌患者外周血中的CTC动态变化，以制定治疗反应和预后标准。我们在治疗开始前检测CTC，并在治疗期间监测其变化，将这些与通过标准成像方法评估的反应相关联。治疗过程中CTC数量的减少与良好的肿瘤反应相关，而CTC计数稳定则表明无反应且生存预后不良。分析了患者的总生存期（OS），并与外周血样本中初始CTC数量进行比较。与基线时总CTC≤3个的患者相比，基线时总CTC>3个的患者中位OS显著缩短（分别为中位生存期26个月，n = 10，与中位生存期8个月，n = 19，HR = 2.6，95%CI 1.07至6.4）。
